Table 2.
Delay-7 model coefficients for the complete case cohort and imputed cohort
| Complete case |
Imputed data |
|||||
|---|---|---|---|---|---|---|
| Variable | Beta coefficient Complete case |
SE Complete case |
P value | Beta coefficient | SE | P value |
| Hospital | ||||||
| 1 | Ref | Ref | Ref | Ref | Ref | Ref |
| 2 | −11.12 | 542.7 | 0.98 | 11.66 | 696.15 | 0.98 |
| 3 | −11.64 | 542.7 | 0.98 | 12.15 | 696.15 | 0.98 |
| 4 | −11.8 | 542.7 | 0.98 | 12.25 | 696.15 | 0.98 |
| Chemotherapy | ||||||
| EC | Ref | Ref | Ref | Ref | Ref | Ref |
| FEC | 0.09 | 0.23 | 0.68 | 0.14 | 0.20 | 0.50 |
| Docetaxel | −0.23 | 0.30 | 0.25 | −0.10 | 0.30 | 0.70 |
| FOLFOXIRI | 1.57 | 0.69 | 0.02 | 1.84 | 0.60 | 0.03 |
| IrMdG | 0.62 | 0.45 | 0.17 | 0.60 | 0.38 | 0.11 |
| OXCAP | 0.43 | 0.30 | 0.15 | 0.50 | 0.27 | 0.26 |
| FOLFOX | 0.46 | 0.46 | 0.31 | 0.60 | 0.39 | 0.26 |
| R-CHOP | −0.04 | 0.27 | 0.87 | 0.20 | 0.25 | 0.94 |
| Cycle length | ||||||
| 14 Days | Ref | Ref | Ref | Ref | Ref | Ref |
| 21 Days | −0.04 | 0.37 | 0.25 | −0.48 | 0.30 | 0.12 |
| Dose reduction received | −11 | 542 | 1.00 | −11.5 | 696 | 1.00 |
| CSF received | 0.05 | 0.17 | 0.80 | 0.003 | 0.16 | 0.90 |
| Body mass index | 0.05 | 0.08 | 0.50 | 0.02 | 0.07 | 0.07 |
| Age | 0.01 | 0.04 | 0.22 | 0.003 | 0.10 | 0.10 |
| Sex | ||||||
| Female | Ref | Ref | Ref | Ref | Ref | Ref |
| Male | −0.23 | 0.12 | 0.06 | −0.22 | 1.10 | 0.05 |
| Ethnicity | ||||||
| Non-white | Ref | Ref | Ref | Ref | Ref | Ref |
| White origin | 0.14 | 0.12 | 0.26 | 0.14 | 0.12 | 0.27 |
| Performance status | ||||||
| 0 | Ref | Ref | Ref | Ref | Ref | Ref |
| 1 | 0.16 | 0.15 | 0.28 | 0.12 | 0.14 | 0.30 |
| 2+ | 0.59 | 0.29 | 0.04 | 0.46 | 0.27 | 0.09 |
| Neutrophils (×109/l) | ||||||
| <2 | Ref | Ref | Ref | Ref | Ref | Ref |
| 2-7 | −0.61 | 0.23 | 0.01 | −0.53 | 0.21 | 0.4 |
| >7 | −0.31 | 0.24 | 0.20 | −0.29 | 0.23 | 0.1 |
| Haemoglobin (g/dl) | ||||||
| <8 | Ref | Ref | Ref | Ref | Ref | Ref |
| 8-10 | 0.18 | 0.65 | 0.79 | 0.12 | 0.67 | 0.86 |
| >10 | −0.01 | 0.64 | 1.00 | 0.04 | 0.66 | 1.00 |
| Creatinine (μmol/l) | ||||||
| <110 | Ref | Ref | Ref | Ref | Ref | Ref |
| 110-165 | 0.20 | 0.19 | 0.30 | 0.62 | 0.17 | 0.72 |
| >165 | 0.18 | 0.24 | 0.46 | 0.16 | 0.22 | 0.46 |
| Bilirubin (μmol/l) | ||||||
| <22 | Ref | Ref | Ref | Ref | Ref | Ref |
| 22-33 | 0.40 | 0.34 | 0.24 | 0.36 | 0.30 | 0.24 |
| >33 | −0.06 | 0.47 | 0.90 | 0.96 | 0.46 | 0.84 |
CSF, colony stimulating factors; EC, epirubicin and cyclophosphamide; FEC, fluorouracil, epirubicin, cyclophosphamide; FOLFOX, oxaliplatin and fluorouracil; FOLFOXIRI, fluorouracil, oxaliplatin, irinotecan; IrMdG, irinotecan modified de gramont: irinotecan, fluorouracil; OXCAP, oxaliplatin and capecitabine; R-CHOP, rituximab, cyclophosphamide, vincristine and prednisolone; SE, standard error.